Alemtuzumab-induced petechiae and epistaxis in a patient with relapsing-remitting multiple sclerosis: A case report

被引：1
|
作者：
Mahmoudi, Farhad [1 ]
Emami, Sayed Ali [1 ]
Masaeli, Farid [1 ]
Rayatpisheh, Najmeh [2 ]
机构：
[1] Isfahan Univ Med Sci, Med Sch, Esfahan, Iran
[2] Shahrekord Univ Med Sci, Sch Med, Shahrekord, Iran
来源：
CLINICAL CASE REPORTS | 2023年 / 11卷 / 11期
关键词：
alemtuzumab; DMT; epistaxis; immune thromboctopenic purpura; ITP; MS; multiple sclerosis; RRMS;
D O I：
10.1002/ccr3.8143
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Here, we present a case of relapsing-remitting multiple sclerosis that experienced petechiae and epistaxis following treatment with second dose of alemtuzumab. This study highlights such effects, emphasizing the need for vigilance as alemtuzumab usage increases. Timely recognition and management are vital for patient care. Alemtuzumab-induced petechiae and epistaxis in a patient with relapsing-remitting multiple sclerosis.image
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Case Report: Delayed Alemtuzumab-Induced Concurrent Neutropenia and Thrombocytopenia in Relapsing-Remitting Multiple Sclerosis
    Ganju, Akaansha
    Stock, James C.
    Jordan, Kim
    [J]. JOURNAL OF PHARMACY PRACTICE, 2023, 36 (01) : 168 - 172
  • [2] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [3] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    [J]. IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [4] Acute motor axonal neuropathy following alemtuzumab treatment in relapsing-remitting multiple sclerosis patient - a case report
    Hradilek, P.
    Woznicova, I.
    Slonkova, J.
    Zeman, D.
    Zapletalova, O.
    Cabal, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 344 - 344
  • [5] Alemtuzumab induced anti-glomerular basement syndrome in a patient with relapsing-remitting multiple sclerosis
    Walendy, Victor
    Greinert, Daniel
    [J]. NEUROLOGY AND CLINICAL NEUROSCIENCE, 2020, 8 (05): : 346 - 347
  • [6] NatalizumabExacerbation of relapsing-remitting multiple sclerosis: case report
    [J]. Reactions Weekly, 2018, 1695 (1) : 278 - 278
  • [7] NatalizumabExacerbation of relapsing-remitting multiple sclerosis: case report
    [J]. Reactions Weekly, 2016, 1623 (1) : 144 - 144
  • [8] Cerebral toxoplasmosis in patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab
    Raquel, Calle-Calle
    Lucia, Triguero-Cueva
    Carmen, Valderrama-Martin
    Ana, Romero-Villarrubia
    Antonio, Tapia-Gomez
    Juan, Pasquau-Liano
    Carmen, Arnal-Garcia
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
  • [9] Listeria monocytogenes meningitis after course of alemtuzumab for relapsing-remitting multiple sclerosis - a case report
    Hradilek, P.
    Hon, P.
    Zeman, D.
    Zapletalova, O.
    Woznicova, I.
    Cabal, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 922 - 923
  • [10] Alemtuzumab/fingolimodSevere activation of relapsing-remitting multiple sclerosis: 3 case reports
    [J]. Reactions Weekly, 2018, 1714 (1) : 25 - 25
12345